Navigation Links
Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
Date:9/25/2007

HORSHAM, Pa., Sept. 25 /PRNewswire/ -- Findings from an international, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating ustekinumab (CNTO 1275) in the treatment of moderate to severe plaque psoriasis will be presented for the first time at the 21st meeting of the World Congress of Dermatology, which takes place from Sept. 30 to Oct. 5, 2007 in Buenos Aires, Argentina.

The presentation, entitled CNTO 1275 (anti-IL-12/23p40) Treatment of Psoriasis: Phase 3 Trial Results will take place on Wednesday, Oct. 3, 2007 from 11 a.m. to 1 p.m. local time (GMT +3:00; 10:00 a.m. to 12:00 p.m. EDT), Room A, La Rural Convention Center, Buenos Aires, Argentina.

These first reported findings will be the subject of a live press briefing and webcast, which will be broadcast from the World Congress of Dermatology on Wednesday, Oct. 3 at 2 p.m. EDT. Media and analysts are invited to register at http://www.CNTO1275WCD.com and listen live on Oct. 3 as investigators from the trial will review and discuss the data.

About Ustekinumab

Ustekinumab is a new, fully-human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis and is being investigated as an infrequently-administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in normalizing the immune system and that are also believed to play a role in immune-mediated inflammatory diseases.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies will market ustekinumab in all countries outside of the United States.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease that results from inflammation in the skin and overproduction of skin cells that accumulate on the surface causing red, scaly plaques that may itch and bleed. This chronic inflammation is driven in part by IL-12 and IL-23, cytokines involved in the regulation of the body's immune response. It is estimated that 125 million people worldwide have psoriasis, including two percent of both the U.S. and European populations, or some 7.5 million Americans and 10 million Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor, Inc. is a wholly owned subsidiary of Johnson & Johnson.

About Janssen-Cilag

The Janssen-Cilag companies are members of the Johnson & Johnson Family of Companies, the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. Janssen-Cilag companies have a long track record in developing and marketing treatments for central nervous system disorders, pain management, infectious diseases, gastrointestinal disorders and oncology.


'/>"/>
SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... May 25, 2016 Digital Health Dialog, ... it by the US Patent and Trademark Office ... includes proprietary processes for electronic opt-­in and processing ... wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for individuals ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
(Date:5/24/2016)... , May 24, 2016  NxStage Medical, Inc. (Nasdaq: ... focused on advancing renal care, today announced that ... participate in the following schedule of investor conferences. Where ... available at http://ir.nxstage.com/ .   ... Healthcare Conference NY, NY           Friday, June 10, 2016 ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... The Woodlands at John Knox Village , Florida’s first ... for living and healing, celebrated its grand opening, today. The Woodlands at John Knox ... by Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village ...
(Date:5/26/2016)... TN (PRWEB) , ... May 26, 2016 , ... There ... and more than 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities ... 29th annual National Cancer Survivors Day®. , National Cancer Survivors Day® is an ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... , ... May 26, 2016 , ... An April Gallup ... families. , The 550 employees of Sun Health Senior Living (SHSL) may ... that reduces their doctor and prescription copays for the year, while holding the line ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial start ... is sharing tips to make sure your family and vehicle are ready to hit ... there may be 439 deaths and an additional 50,500 serious injuries from motor vehicle ...
Breaking Medicine News(10 mins):